![VJHemOnc Podcast](https://pbcdn1.podbean.com/imglogo/image-logo/8189927/VJH_Thumbnail_1400b48w2.jpg)
58.4K
Downloads
272
Episodes
The Video Journal of Hematology and Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
Episodes
![Key updates on CAR-T therapy for multiple myeloma](https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog8189927/GettyImages-1303505360_copy65wok_300x300.jpg)
Monday Aug 02, 2021
Key updates on CAR-T therapy for multiple myeloma
Monday Aug 02, 2021
Monday Aug 02, 2021
The treatment of multiple myeloma is a rapidly evolving field with advances in the understanding of myeloma disease biology contributing to the development of novel targeted therapies. Recently, there has been a rapid increase in the number of chimeric antigen receptor (CAR) T-cell therapies being trialed for patients with multiple myeloma, and in March 2021, idecabtagene vicleucel became the first CAR-T therapy to receive FDA approval for the treatment of myeloma.
In this podcast, Nina Shah of the University of California San Francisco, CA; Saad Usmani of the Levine Cancer Institute, NC; Sham Mailankody of the Memorial Sloan Kettering Cancer Centre, NY; Adam Cohen of the Abramson Cancer Centre, PA; and Maria-Victoria Mateos of the University Hospital of Salamanca, Spain, discuss the use of CAR-T therapy in patients with multiple myeloma.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.